Canadian Cancer Society / Lotte and John Hecht Memorial Foundation Disruptive Innovation Grants in Cancer Research

Canadian Cancer Society

Letter of Intent Application Guide
January 2024
Version 1

Deadline dates

Letter of Intent (competitive) due date: March 21st, 2024 @5pm ET

Full application (invited/competitive) due date: August 1st, 2024

Results announcement: mid-December, 2024

Anticipated funding start: January 15th, 2025

To Apply

Complete the Letter of Intent Application Form here :
https://canadiancancersociety.questionpro.ca/disruptiveinnovationloi2024

Applications may be saved for completion at a later date.

The full application stage will be completed in CCS's online grants management system – EGrAMS.

For Questions

Contact CCS research at research@cancer.ca.

Note

Please read the program description on the CCS website carefully prior to submitting the Letter of Intent application. Applications that fail to adhere the program, eligibility, or other CCS guidelines will be withdrawn.

Complete your application

Administrative Information (not shared with reviewers):

Project Title:	*Enter the project title. Avoid typing in ALL CAPS. Ensure spelling and punctuation is correct.*
Principal Investigator (PI) First Name:	*Enter the lead applicant's First Name. Please ensure that this individual is qualified to act as a Principal Investigator (see https://cancer.ca/en/research/for-researchers/managing-your-grant/eligibility-and-requirements). Also note that for this competition there is a limit of one application per nominated PI or Co-PI.*
PI Last Name:	*Enter the lead applicant's Last Name.*
PI Institution:	*Enter the lead applicant's Primary institution name. Ideally this will also be the institution where funds will be administered if the grant is successful.*
Department:	*Indicate the lead applicant's Department name.*
City:	*Indicate the City in which the Institution of the lead applicant is situated.*
Province:	*Indicate the Province in which the Institution of the lead applicant is situated.*
Country:	*Indicate the Country in which the Institution of the lead applicant is situated. Note that this **MUST** be entered as Canada to be eligible for funding.*
Email address:	*Indicate the professional (work) email address of the lead applicant.*
Host Institution responsible for administering grant funds:	*If the institution responsible for administering grant funds is different from the institution of the PI, please indicate this here.*
Will this application be submitted in French? (Note that review process will be conducted in English)	*Indicate Yes or No* *Complete the entire application in one language only.*
Review the role types and eligibility here (https://cancer.ca/en/research/for-researchers/managing-your-grant/eligibility-and-requirements)	*Enter the Name, Role (type), Institution (if applicable), Province, Country and Email address for all team members known at the LOI stage.* *Roles can include: Co-Principal Investigators, Co-applicants, Additional Authors, Knowledge Users (or Implementers/Decision-makers), and Patient/Survivor/Caregivers.*

Additional team members may be added at the full application stage.	
Please indicate Yes or No to these questions -	• *First application (as PI) for a research grant to the Canadian Cancer Society (Yes/No)* • *First application (as PI) for a research grant to the Lotte and John Hecht Memorial Foundation (Yes/No)* • *First application (as PI) for a research grant focused on cancer (Yes/No)* • *First application (as PI) for a research grant (Yes/No)*
Please select the appropriate career stage of the PI:	• *New/early career investigator: Any applicant who, at the time of LOI submission, assumed their first independent academic position no more than 5 years ago* • *Mid-career investigator: Any applicant who, at the time of LOI submission, assumed their first independent academic position 5-15 years ago* • *Senior investigator: Any applicant who, at the time of LOI submission, assumed their first independent academic position more than 15 years ago*

Project Information (shared with reviewers):

NOTE: Please ensure that <u>no team identifiers</u> are present in any of the content provided in this section. If any identifying information is provided (names, institutions, locations) the LOI application will be disqualified without contest.

Public Summary	*Please provide a lay description of the proposed project and its potential impact. Include the goal/purpose of your project, what you are proposing to achieve, and why 'now' is the time to do it.* *Maximum 1000 characters (including spaces).*
Proposal	*Provide a brief proposal summarizing:* • *The project to be undertaken, including overall goal, aims, and rationale* • *How this proposal is novel, bold and intriguing* • *Why 'now' is the time to do it – and 'why' it hasn't been attempted (or achieved) before* • *A description – without compromising anonymity – of the expertise brought together for this application, and whether the team comprises new collaborations* • *A description of how the project could – if successful – revolutionize the prevention, detection and/or treatment of cancer* *Maximum 6000 characters (including spaces).*

Keywords	*Provide up to a maximum of 10 specific keywords or descriptive terms that best describe the focus and approach of your project. Enter one keyword or term per line.*
Research Focus	*Select the <u>single</u> research focus that best fits with the scope of the proposed project:* • *Biomedical research - Projects that rely on model systems or are basic/fundamental research. Includes understanding disease mechanisms or studying cell pathways in model systems, PDX, or patient-derived cell lines. Only if any component of the project involves human "participants", it should be coded as clinical research.* • *Clinical research - Projects that have a component that is clinical and involves human subjects. Includes companion clinical trials and correlative studies as well as psychosocial oncology research. Generally, involves humans or samples from humans. Includes interventions such as drugs, exercise or other programs, biomarkers, or mechanism of action of drugs in patients (or liquid biopsies).* • *Health systems and health services research - Research that assesses or attempts to solve barriers to care, treatment adherence, care utilization, overtreatment, health care transitions, national strategies/frameworks, clinical pathways/guidelines, ethics, patient decision aids, adverse drug reactions, treatment delays/wait times, access/equity, and/or health literacy.* • *Social, cultural, environmental, and population health research – Research that is population-level and unrelated to the health system. Includes research that investigates lifestyle, toxin exposures, diet, or population-based surveillance surveys (e.g., the International Tobacco Control (ITC) survey, British Columbia Adolescent Substance Use Survey).*

Authorization for release:

Acknowledgement of the following statements are required to complete the submission of an application to CCS.

CCS depends on donor dollars to fund its research grants and awards.

- Applicants must declare their willingness to allow CCS and the Hecht Foundation to confidentially provide minimal details of their application (and if relevant, funded grant/award) to potential donors and/or partners. Donors/partners will be required to declare conflicts of interest and sign a confidentiality agreement before any information is shared. If the research is not funded, all shared information will be destroyed.

- For successful grantees/awardees, CCS and the Hecht Foundation will share competition results (PI, institution, team members, title, value and term of grant, non-confidential abstract or summary), as well as progress updates and research impacts publicly (with permission) in multiple formats internally and externally, including on our website, in press releases, annual impact reports, social media, or other communications.
- Funded grantees/awardees must agree to reasonable (proportional to funding received) requests in support of marketing, fundraising and communication efforts to enable continued support of our mission. To that end, grantees/awardees will be requested to share photos, videos, bios and other information at the time of funding, and participate in other activities from time to time as (reasonably) requested.

Please indicate your acknowledgement and agreement to the statements above prior to submitting your application. If you select 'No' for this question, please be advised that your application will be withdrawn.

Submit your application

Once you are satisfied with the accuracy and completeness of the application, please 'Submit' the application via the button provided. Applications must be submitted by the deadline of March 21st, 2024 at 5pm ET.

No further action is necessary. Applicants will be advised of results via email by the end of May, 2024. Successful applicants will be invited to submit their full application via EGrAMS by August 1st, 2024 at 5pm ET.